Trial · NCT05694819
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
NCT05694819, Phase 2, Completed, National Cancer Center Hospital East
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY). Trials, record NCT05694819. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05694819
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
- NCT number
- NCT05694819
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 57 participants, actual
- Lead sponsor
- National Cancer Center Hospital East
- Conditions
- Salivary Gland Cancer
- Interventions
- Darolutamide, Goserelin
- First posted
- 2023-01-23
- Last updated
- 2026-04-08
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Darolutamide monotherapy group: Objective response rate(ORR) assessed by investigators | Up to 13 month | The proportion of patients with confirmed tumor response of complete response (CR) or partial response (PR) per RECIST 1.1, as assessed by investigators |
| Primary | Darolutamide and Goserelin combination therapy group: Objective response rate(ORR) assessed by an Independent Review Committee | Up to 13 month | The proportion of patients with confirmed tumor response of CR or PR per RECIST 1.1, as assessed by an independent review committee |
| Secondary | Duration of Response (DOR) | Up to 13 month | DOR will be defined among responders from the date of initial documentation of a response (CR or PR) to the date of first documented evidence of progressive disease as defined in RECIST version 1.1 or death, whichever occurred first. |
| Secondary | Best Overall Response (BOR) | Up to 13 month | BOR will be defined as the best response recorded from the start of protocol treatment based on RECIST version 1.1 |
| Secondary | Disease Control Rate (DCR) | Up to 13 month | DCR will be defined as the percentage of participants who achieved a confirmed best overall response of CR, PR, or SD for at least 6 weeks based on RECIST version 1.1. |
| Secondary | Clinical Benefit Rate (CBR) | Up to 13 month | CBR will be defined as the percentage of participants who achieved a confirmed best overall response of CR, PR, or stable disease (SD) for at least 24 weeks based on RECIST version 1.1. |
| Secondary | Clinical Benefit Duration (CBD) | Up to 13 month | CBD will be defined the period starting from the date of enrollment (start of treatment) and ending on the earlier of the date of determination of progression, the date of death from any cause, or the end of the study period. |
| Secondary | Progression-Free Survival (PFS) | Up to 13 month | PFS will be defined as the time from the date of the initial dose of study intervention to the date of first documented disease progression as defined in the RECIST version 1.1, or death due to any cause, whichever occurred first. |
| Secondary | Overall Survival (OS) | Up to 13 month | OS will be defined as the time from the date of the initial dose of study intervention to the date of the participant's death |
| Secondary | Adverse events | Up to 30 days after the last dose | All adverse events, adverse events with undeniable causal relationship to the investigational drug, severe adverse events (SAEs) and SAEs with undeniable causal relationship to the investigational drug will be evaluated based on CTCAE version 5.0 |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 42546251 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05694819
GET https://conductscience.org/api/trials/v1/NCT05694819/registered